# Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct07081633/  
OnCo record `nct07081633` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Durvalumab, Tremelimumab, Lenvatinib in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.

## Summary

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT07081633 by AstraZeneca, with 114 participants enrolled, started 2025-08-05 and due to reach its primary completion in 2026-11-30. Interventions recorded: Durvalumab, Tremelimumab, Lenvatinib. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07081633
- Phase: 2
- Setting: An Open-label, Multi-center Phase II Study of Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
- Sponsor: AstraZeneca
- Enrolled: 114

## Sources

- ClinicalTrials.gov NCT07081633: https://clinicaltrials.gov/study/NCT07081633

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Tremelimumab](https://onco.cc/drugs/tremelimumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07081633.json